Home » Stocks » LPCN

Lipocine Inc. (LPCN)

Stock Price: $1.62 USD -0.03 (-1.82%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.60 -0.02 (-1.24%) Jan 15, 7:37 PM
Market Cap 104.77M
Revenue (ttm) n/a
Net Income (ttm) -19.75M
Shares Out 64.83M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.62
Previous Close $1.65
Change ($) -0.03
Change (%) -1.82%
Day's Open 1.67
Day's Range 1.56 - 1.68
Day's Volume 1,822,127
52-Week Range 0.32 - 2.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 day ago

SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Pa...

PRNewsWire - 2 weeks ago

SALT LAKE CITY, Dec. 30, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is ...

PRNewsWire - 2 weeks ago

SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge ...

Seeking Alpha - 1 month ago

LPCN's long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval.

PRNewsWire - 1 month ago

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...

PRNewsWire - 1 month ago

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an inde...

PRNewsWire - 1 month ago

SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...

Insider Monkey - 1 month ago

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete ...

Seeking Alpha - 2 months ago

Lipocine is about to report data from its clinical study on whether TLANDO can restore testosterone levels in hypogonadal men without the dose titration requirement on November 9, 2020. Low ba...

PRNewsWire - 2 months ago

SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S...

PRNewsWire - 4 months ago

SALT LAKE CITY, Aug. 28, 2020 /PRNewswire/ -- Lipocine Inc.

PRNewsWire - 5 months ago

SALT LAKE CITY, Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc.

PRNewsWire - 5 months ago

SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Lipocine Inc.

PRNewsWire - 6 months ago

SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has...

PRNewsWire - 8 months ago

SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinica...

24/7 Wall Street - 1 year ago

Lipocine Inc. (NASDAQ: LPCN) shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter (CRL) from the U.S.

Benzinga - 1 year ago

Lipocine Inc (NASDAQ: LPCN) shares are tumbling to record lows after an adverse FDA verdict on its lead drug Tlando, previously known as LPCN 1021.

Market Watch - 1 year ago

Shares of Lipocine Inc. LPCN, -2.50% plummeted 67% toward a record low, and to pace all premarket losers, after the biopharmaceutical company said the Food and Drug Administration indicated th...

Benzinga - 1 year ago

Lipocine Inc is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate.

About LPCN

Lipocine, a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. I... [Read more...]

Industry
Biotechnology
CEO
Mahesh Patel
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
LPCN
Full Company Profile

Financial Performance

In 2019, Lipocine's revenue was $164,990, a decrease of -61.45% compared to the previous year's $428,031. Losses were -$13.01 million, 11.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Lipocine stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 229.01% from the latest price.

Price Target
$5.33
(229.01% upside)
Analyst Consensus: Buy